A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD

NCT ID: NCT07269769

Last Updated: 2025-12-15

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 450 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2031-12-31

Brief Summary

The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.

Conditions

AMD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Experimental Group

Sanhuang Jingshiming Pills，1 sachet/dose, bid

Group Type: EXPERIMENTAL

Sanhuang Jingshiming/Pills placebo

Intervention Type: DRUG

Ranibizumab: 1 dose/study eye (Screening/Baseline), then PRN injections

Placebo Group

Placebo，1 sachet/dose, bid

Group Type: PLACEBO_COMPARATOR

Sanhuang Jingshiming/Pills placebo

Intervention Type: DRUG

Ranibizumab: 1 dose/study eye (Screening/Baseline), then PRN injections

Interventions

Sanhuang Jingshiming/Pills placebo

Ranibizumab: 1 dose/study eye (Screening/Baseline), then PRN injections

Intervention Type: DRUG

Other Intervention Names

Ranibizumab

Eligibility Criteria

Inclusion Criteria

1. Aged 50 to 85 years old (inclusive of 50 and 85 years old)

2. Meets the Western medical diagnostic criteria for neovascular age-related macular degeneration

3. Meets the TCM syndrome differentiation criteria for Qi-Yin Deficiency with Phlegm-Blood Stasis Intermingling Syndrome

4. The study eye is diagnosed with nAMD and the disease is in the active phase

5. BCVA of the study eye assessed by the ETDRS visual acuity chart ranges from 25 to 78 letters

6. Voluntarily participates in the clinical trial, signs the ICF, and is able to understand and comply with the trial procedures

Exclusion Criteria

1. The study eye is complicated with pathologic myopia, high myopia, or secondary MNV caused by other definite diseases, glaucoma, diabetic retinopathy , retinal artery/vein occlusion , optic neuropathy (optic neuritis, optic atrophy, papilledema), macular hole, acute phase of intraocular inflammation, or other ocular diseases

2. Patients with pure PED in the study eye

3. Patients with subfoveal structural destruction or subfoveal fibrosis/scars/RPE tear/GA in the study eye

4. Patients whose FP of the study eye shows a total macular lesion area > 9 disc areas (total lesion area is defined as the sum of the areas of MNV, atrophy, scars, and fibrosis); or patients whose FP of the study eye shows a maximum macular hemorrhage area > 4 disc areas

5. Patients with CRT ≥ 700 μm in the study eye as assessed by OCT

6. Patients with opaque refractive media (e.g., vitreous hemorrhage, cataract) in the study eye precluding adequate visualization of the fundus, or with a history of vitrectomy

7. Patients planning to undergo any intraocular surgery on the study eye during the trial period

8. Patients who received pharmacologic treatment for nAMD within 2 weeks prior to randomization

9. Patients who received intravitreal anti-vascular endothelial growth factor therapy on the study eye within 4 months prior to randomization

10. Patients who received photodynamic therapy , laser photocoagulation, macular surgery, transpupillary thermotherapy , or corticosteroid therapy on the study eye within 6 months prior to randomization

11. Patients who underwent any intraocular or periocular surgery (excluding eyelid surgery) on the study eye within 3 months prior to randomization

12. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg while on regular antihypertensive medication)

13. History of major cardiovascular or cerebrovascular diseases, including but not limited to: ① history of myocardial infarction (MI), coronary angioplasty or bypass surgery, valvular heart disease or valvular repair, clinically significant and treatment-requiring arrhythmia, unstable angina, transient ischemic attack (TIA), cerebrovascular accident (CVA), etc., within 6 months prior to randomization; ② congestive heart failure (CHF) with New York Heart Association (NYHA) classification of Grade Ⅲ or Ⅳ

14. Laboratory test abnormalities as follows: ① platelet count ≤ 100 × 10⁹/L; ② International Normalized Ratio (INR) ≥ 1.5; ③ total bilirubin (TBIL) > 2 × upper limit of normal (ULN); ④ alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN; ⑤ serum creatinine (Scr) > 1.5 × ULN

15. Patients with severe and unstable diseases of the mental, neurological, respiratory, digestive, renal, metabolic, immune, hematologic, or other systems, as well as malignant tumors, who are assessed by the investigator as unsuitable for participation in this clinical trial

16. Presence of any contraindications listed in the package insert of ranibizumab injection (Lucentis®) or other anti-VEGF injections

17. Suspected allergy to any study drug

18. Pregnant or lactating females; males or females who plan to conceive within 30 days from signing the ICF to the end of the trial, or who cannot use effective contraceptive measures

19. Participation in another interventional clinical trial within 3 months prior to randomization

20. Other reasons deemed unsuitable for participation in this clinical trial by the investigator

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tasly Pharmaceutical Group Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Hospital

Beijing, , China

Countries

China

Central Contacts

Rui Liu

Role: CONTACT

liurui383@taslypharma.com

022-86343626

Facility Contacts

Hong Dai, Doctor

Role: primary

Dai-hong@x263.net

13910280398

Other Identifiers

TSL-TCM-SHJSMW-Ⅲ

Identifier Type: -

Identifier Source: org_study_id